옵션 체인은 다양한 행사가격과 만기일에 대한 Borr Drilling의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Borr Drilling에 대한 시장 심리를 평가합니다..

Borr Drilling (NYSE:BORR) 주식, 옵션 체인

Borr Drilling

Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.

LiAuto.Shutterstock

Large Cap

News

Movers

Trading Ideas

APTV

BORR

CHKP

MPWR

SMCI

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)의 주식은 독립 감사인인 언스터 &amp; 영(Ernst &amp; Young)의 사임 소식이 전해진 후 44.89% 하락했다. 아거스 리서치(Argus Research)는 매수에서 보유로 등급을 하향 조정했다.

슈퍼 마이크로 및 에스티 로더는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 28일-11월 1일)

Borr Drilling Ltd

Borregaard ASA

BORROWMONEY.COM INC by BorrowMoney.com inc.

BorrowMoney.com Inc

Hovde Group analyst Brendan Nosal upgrades First Savings Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSFG#NASDAQ">FSFG</a>) from Market Perform to Outperform.

Upgrades

Analyst Ratings

FSFG

Hovde Group Upgrades First Savings Financial to Outperform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Compass Point analyst Joe Flynn downgraded the rating for MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) from Neutral to Sell and lowered the price target from $25 to $9.5. MARA Holdings shares closed at $13.09 on Monday. <a href="https://www.benzinga.com/quote/MARA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst David Risinger downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Outperform to Market Perform and cut the price target from $550 to $503. Vertex Pharmaceuticals shares closed at $500.19 on Monday. <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jenny Ping downgraded the rating for National Grid plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGG#NYSE">NGG</a>) from Buy to Neutral. National Grid shares closed at $71.84 on Monday. <a href="https://www.benzinga.com/quote/NGG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JWedbush analyst Michael Pachter downgraded Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) from Outperform to Neutral and lowered the price target from $21 to $9. Turtle Beach shares closed at $10.76 on Monday. <a href="https://www.benzinga.com/quote/tbch/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="623" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-1024x623.png" alt="" class="wp-image-903019" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

MARA

RDDT

TBCH

VRTX

This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) affirms FY2025 sales outlook from $540.00 million-$580.00 million to $540.00 million-$580.00 million vs $543.72 million estimate.

Guidance

FSTR

L.B. Foster Affirms FY2025 Sales Guidance of $540.00M-$580.00M vs $543.72M Est

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and lowers the price target from $90 to $86.

Price Target

HSIC

Barrington Research Maintains Outperform on Henry Schein, Lowers Price Target to $86

<a href="https://innoviz.tech/">Innoviz Technologies Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) (the "Company" or "Innoviz"), a leading Tier-1 direct supplier of high-performance, automotive-grade LiDAR sensors and perception software, today announced an expansion of the multi-year NRE (Non-Recurring Engineering) payment plan initially announced in December 2024. The NRE payment plan is the outcome of development activities that Innoviz has performed and will continue to perform for its key existing customers. The expansion of the NRE payment plan is expected to further bolster the Company's financial position, bringing the total cash payments anticipated from the plan to approximately $95 million from $80 million between 2025 and 2027. These payments will be incremental to revenues generated from ongoing sales of LiDAR products to existing customers and new orders coming from additional programs.

INVZ

Innoviz Technologies Expands Multi-Year Non-Recurring Engineering Payment Plan

Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platform to Enable Effective Oral Delivery of Therapeutics, Today Announced That It Has Entered Into License and Supply Agreement With Aché Laboratórios Farmacêuitcos s.a (Aché) Granting Exclusive Rights to Market Tlando&#xAE; in Brazil.
The market for prescription testosterone products in Brazil is substantial and rapidly growing with compound annual growth rate (CAGR) of 34% from 2019 to 2023 and no oral testosterone therapy registered in Brazil.
"We are pleased to partner with Aché, one of the leaders in the Brazilian pharmaceutical market, to further expand the opportunity for TLANDO," said Mahesh Patel, CEO of Lipocine. "Brazil represents an important new growth market, and Aché's established commercial capabilities and proven regulatory expertise make them an ideal partner to bring TLANDO to patients in Brazil."
Under the terms of the agreement, Lipocine has received an upfront payment and is eligible to receive additional payments upon the achievement of certain regulatory milestones and royalties on net sales. Aché assumes full responsibility for the regulatory submission and approval process in Brazil.

Biotech

Contracts

General

LPCN

Lipocine Enters Into License And Supply Agreement With Aché Laboratórios Farmacêuitcos S.A Granting Exclusive Rights To Market Tlando in Brazil.

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $0.04 by 600 percent. This is a 350 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $97.79 million which missed the analyst consensus estimate of $113.16 million by 13.58 percent. This is a 21.34 percent decrease over sales of $124.32 million the same period last year.

Earnings

Earnings Misses

L.B. Foster Q1 EPS $(0.20) Misses $0.04 Estimate, Sales $97.79M Miss $113.16M Estimate

Financial Guidance
The following guidance is based on current market conditions and expectations and the information available to the Company today. For 2025 Talkspace continues to expect:
<ul>
<li>Revenue to be in the range of $220 million to $235 million</li>
<li>Adjusted EBITDA to be in the range of $14 million to $20 million</li>
</ul>

TALK

Talkspace Affirms FY2025 Sales Guidance of $220.00M-$235.00M vs $226.60M Est

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.34 by 41.18 percent. This is a 45.95 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $663.00 million which missed the analyst consensus estimate of $679.49 million by 2.43 percent. This is a 6.22 percent decrease over sales of $707.00 million the same period last year.

WK Kellogg Q1 EPS $0.20 Misses $0.34 Estimate, Sales $663.00M Miss $679.49M Estimate

Business Outlook and Financial Guidance
"The first quarter book-to-bill ratio was solidly above one and we entered the second quarter with a strong outlook given the bookings momentum. While recent tariffs have caused uncertainty related to the timing of shipments and some increased costs in the near term, we are able to take advantage of our global manufacturing footprint and supply chain to mitigate their impact while continuing to invest in the future growth of our business," concluded Dr. Gitin.
For the second quarter of 2025, IPG expects revenue of $210 million to $240 million Our revenue guidance is approximately $15 million lower than it would have been due to potential shipment delays related to tariffs. These are not order cancellations and the Company expects to fulfill these orders as it optimizes production across its global footprint. The Company expects second quarter adjusted gross margin to be between 36% and 38%, including 150 to 200 basis points of impact from tariffs, and operating expenses of $86 million to $88 million. IPG anticipates delivering adjusted earnings per diluted share in the range of -$0.05 to $0.25 and adjusted EBITDA in the range of $16 million to $31 million.

IPGP

IPG Photonics Q2 Outlook: Adj EPS $(0.05)-$0.25 vs $0.31 Est; Sales $210.000M-$240.000M vs $242.19M Est

Buybacks

HESM

Hess Midstream LP Signs Accretive $200M Repurchase From Sponsors And Public

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $38.90 million which beat the analyst consensus estimate of $37.42 million by 3.97 percent. This is a 12.21 percent increase over sales of $34.67 million the same period last year.

Earnings Beats

HRTX

Heron Therapeutics Q1 EPS $0.01 Beats $(0.01) Estimate, Sales $38.90M Beat $37.42M Estimate

J&amp;J Snack Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.72 by 51.39 percent. This is a 58.33 percent decrease over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $356.10 million which missed the analyst consensus estimate of $367.04 million by 2.98 percent. This is a 1.01 percent decrease over sales of $359.73 million the same period last year.

JJSF

J&J Snack Foods Q2 Adj. EPS $0.35 Misses $0.72 Estimate, Sales $356.10M Miss $367.04M Estimate

Talkspace Q1 2025 Sales $52.18M Miss $53.31M Estimate

Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. This is a 37.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $176.44 million which missed the analyst consensus estimate of $180.40 million by 2.20 percent. This is a 6.40 percent increase over sales of $165.83 million the same period last year.

PTLO

Portillos Q1 EPS $0.05, Inline, Sales $176.44M Miss $180.40M Estimate

Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 8 percent decrease over losses of $(0.25) per share from the same period last year.

NVCT

Nuvectis Pharma Q1 EPS $(0.27) Misses $(0.25) Estimate

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The <a href="https://www.globenewswire.com/Tracker?data=sPdlu4TKNZIsHxJEPTmy6FyLva5Ge3rx5UPKl7XVfE1YRsdxrAIFmq309CL0nLPgSv5WPaX_spBjEwC4uQ0KrXWNYhbirikskfe1qcEqzwA1spXxBsqKL5KGOb_P-6tAG9llQx0-2dMk6HuG_sP9Mg==">data</a> is being presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress, taking place from June 11-14, in Barcelona, Spain.
Presentation Title: A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Patients With Moderate-to-Severe Knee Osteoarthritis Through 3 Years
Presented By:&nbsp;Philip G. Conaghan, MB BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, University of Leeds, UK; Director, NIHR Leeds Biomedical Research Centre
Date &amp; Time:&nbsp;Wednesday, June 11 from 3:30 pm – 4:30 pm CEST
About PCRX-201 (enekinragene inzadenovec)
PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company's proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to "wear and tear" over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
Given the promising Phase 1 results, dosing is underway in a <a href="https://www.globenewswire.com/Tracker?data=c5NTS41A9eCJ7pBJDDcVdJl24zDQ5oUQhkXsBarkSENehjkVqxb0mhTlMeR5u4B7txnhAtd41I7RLfCjuDRiXFhwWkEBcDMKQHyg8vlFrIwBmchK9b3nYcwRh1gXCofoiDNQMJEIg-iG8nJw9v___I0HqteHZCvRV6-8wlVVtXa7_cI3BW3Z5F5OoIk_nnTui40yJ0FtHb2t5a5UtEGUCA==">Phase 2</a> study of PCRX-201 (<a href="https://www.globenewswire.com/Tracker?data=D7wLILMMFqdRJlncOrA56lLJsP-QFY5_wdKYIc0-vFYnSmm7GREJ9AszWQrwKWsaS5a4ofVFOHFPsbSZ8A4vlIjs4Lp2YB5KIg7oToeMTAoKdgzvR2muxJugdGtfhrXD_pzvzD_2Wtmdk_DRSzZfAQ==">the ASCEND study</a>) for the treatment of knee osteoarthritis. To learn more about PCRX-201 and the company's <a href="https://www.globenewswire.com/Tracker?data=DRcDeFIJ6lfhc-n94dMXJV9ZiqcHotiJw1VqdV1Csb3Nc1uPEkfNLWcfH_LupAU2OV7bdqpyZOQ7z5aWzAwYOi4AkEacArJ_0iQ9nrmknA8PmRXm_KnSRN_gmzDzuSjde1kjylIKxDK8cmlBkVvnCRftWCyl141-C6uywhgTdT4iyQgLzhDbX9ozD6e7PpYlrx9vzdOzKtei275ETd12wA==">clinical development program</a>, please visit the <a href="https://www.globenewswire.com/Tracker?data=qS5LfB_Ae7WfmI8YxuxgI8hoWWUGsoIFRbve7Blmz5ZVzc4MG-BOQjBmk4NWlB1YP0eQF0m6UDkgPuLGO6rg6FW9KDGNsZIU8ae0PMEjRSA=">investor events</a> section of the company's investor website.

PCRX

Pacira BioSciences Announces It Will Present 3-Year Safety And Efficacy Data of PCRX-201 Following Single Intra-Articular Injection For Moderate-to-Severe Knee Osteoarthritis At 2025 European Alliance Of Associations For Rheumatology June 11-14 2025 In Barcelona, Spain

<ul>
<li>400V high-voltage coolant heater (HVCH) technology to be used in series of plug-in hybrid electric vehicles</li>
<li>HVCH offers flexible and compact design with high thermal power density
<ul>
<li>Marks the company's largest&nbsp;eHeater contract for plug-in hybrid electric vehicles in North America</li>
</ul>
</li>
</ul>

BorgWarner Wins High-Voltage Coolant Heater Contract With Global OEM; Terms Not Disclosed

Uniti Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) lowers FY2025 FFO guidance from $1.40-$1.47 to $1.32-$1.39 vs $1.40 analyst estimate. Affirms FY2025 sales outlook from $1.20 billion-$1.22 billion to $1.20 billion-$1.22 billion vs $2.61 billion estimate.

Comments

Borr Drilling

Borr Drilling (BORR) 옵션

Borr Drilling (NYSE:BORR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌